Studies of insulin action in patients at increased vascular risk: modulation by anti-hypertensive and endocrine replacement therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN84921696

Enrollment

Registered

2008-01-25

Start date

2006-09-19

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, type two diabetes, hypopituitarism Nutritional, Metabolic, Endocrine Hypertension

Interventions

Protocols one and two: Medications will be withdrawn and replaced with placebo for a six week run in. Patients will be randomised to captopril plus study drug (bendroflumethiazide) or captopril plus

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Under 65 years old 2. Protocol one: essential hypertension, mild or newly diagnosed 3. Protocol two: type two diabetes and hypertension 4. Protocol 3: hypopituitarism, female, low basal DHEA levels

Exclusion criteria

Exclusion criteria: 1. Secondary hypertension 2. Obesity 3. Cardiac, renal or hepatic disease 4. History of gout 5. Those in receipt of any additional medications that may affect insulin action 6. Type two diabetics with dipstick positive proteinuria

Design outcomes

Primary

Measure	Time frame
Insulin resistance.	—

Secondary

Measure	Time frame
Quality of life following dehydroepiandrosterone replacement.	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026